<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Lipids Health Dis</journal-id><journal-title>Lipids in Health and Disease</journal-title><issn pub-type="epub">1476-511X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1476-511X-7-46</article-id><article-id pub-id-type="pmid">19014618</article-id><article-id pub-id-type="doi">10.1186/1476-511X-7-46</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Apolipoprotein gene polymorphisms and plasma levels in healthy Tunisians and patients with coronary artery disease</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Bahri</surname><given-names>Raoudha</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>raoudha.bahri@yahoo.fr</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Esteban</surname><given-names>Esther</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>mesteban@ub.edu</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Moral</surname><given-names>Pedro</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>pmoral@ub.edu</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Hassine</surname><given-names>Mohsen</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>Mohsen.Hassine@rns.tn</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Hamda</surname><given-names>Khaldoun Ben</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>Khaldoun.benhamda@rns.tn</email></contrib><contrib id="A6" corresp="yes" contrib-type="author"><name><surname>Chaabani</surname><given-names>Hassen</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>hassenchaabani07@yahoo.fr</email></contrib></contrib-group><aff id="I1"><label>1</label>Laboratoire de G&#x000e9;n&#x000e9;tique Humaine, Facult&#x000e9; de Pharmacie de Monastir, Universit&#x000e9; de Monastir 5000 Monastir, Tunisia</aff><aff id="I2"><label>2</label>Departament de Biologia Animal, Unitat d'Antropologia, Facultat de Biologia, Universitat de barcelona, Barcelona, Spain</aff><aff id="I3"><label>3</label>Laboratoire d'h&#x000e9;matologie, Facult&#x000e9; de Pharmacie de Monastir &#x00026; H&#x000f4;pital Universitaire Fattouma Bourguiba, 5000 Monastir, Tunisia</aff><aff id="I4"><label>4</label>D&#x000e9;partement de cardiologie, H&#x000f4;pital Universitaire Fattouma Bourguiba &#x00026; Facult&#x000e9; de M&#x000e9;decine de Monastir 5000, Monastir, Tunisia</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>17</day><month>11</month><year>2008</year></pub-date><volume>7</volume><fpage>46</fpage><lpage>46</lpage><ext-link ext-link-type="uri" xlink:href="http://www.lipidworld.com/content/7/1/46"/><history><date date-type="received"><day>9</day><month>9</month><year>2008</year></date><date date-type="accepted"><day>17</day><month>11</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Bahri et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Bahri et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Bahri Raoudha raoudha.bahri@yahoo.fr </dc:author><dc:title> Apolipoprotein gene polymorphisms and plasma levels in healthy Tunisians and patients with coronary artery disease </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>Lipids in Health and Disease 7(1): 46-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1476-511X(2008)7:1&#x0003c;46&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1476-511X</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Aim</title><p>To analyze apolipoprotein gene polymorphisms in the Tunisian population and to check the relation of these polymorphisms and homocysteine, lipid and apolipoprotein levels to the coronary artery disease (CAD).</p></sec><sec sec-type="methods"><title>Methods</title><p>In healthy blood donors and in patients with CAD complicated by myocardial infarction (MI) four apolipoprotein gene polymorphisms [APO (a) PNR, APO E, APO CI and APO CII] were determined and plasma levels of total homocysteine, total cholesterol (TC), triglycerides (TG), HDL-cholesterol (HLD-C) and apolipoproteins (apo A-I, Apo B, Apo E) were measured.</p></sec><sec><title>Results</title><p>Analysis of the four apolipoprotein gene polymorphisms shows a relative genetic homogeneity between Tunisian population and those on the other side of Mediterranean basin. Compared to controls, CAD patients have significantly higher main concentrations of TC, TG, LDL-C, apo B and homocysteine, and significantly lower ones of HDL-C, apo A-I and apo E. The four apolipoprotein gene polymorphisms have not showed any significant differences between patients and controls. However, the APO E4 allele appears to be associated to the severity of CAD and to high levels of atherogenic parameters and low level of apo E, which has very likely an anti-atherogenic role.</p></sec><sec><title>Conclusion</title><p>Although APO (a) PNR, APO CI and APO CII genes are analyzed in only few populations, they show a frequency distribution, which is not at variance with that of APO E gene and other widely studied genetic markers. In the Tunisian population the APO E 4 appears to be only indirectly involved in the severity of CAD. In the routine practice, in addition of classic parameters, it will be useful to measure the concentration of apo E and that of Homocysteine and if possible to determine the APO E gene polymorphism.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>Coronary artery disease (CAD) is a multifactorial disease caused by genetic and environmental factors. Apolipoprotein genes involved in lipoprotein synthesis and metabolism are considered excellent candidates for studying the susceptibility to CAD and myocardial infarction (MI) [<xref ref-type="bibr" rid="B1">1</xref>]. Functional variants of genes encoding lipoproteins are responsible in part for between-individual variation in the plasma levels of lipoproteins and, therefore, they are related with the risk for atherosclerosis [<xref ref-type="bibr" rid="B2">2</xref>].</p><p>Among apolipoproteins, apolipoprotein (a) is a highly glycosylated protein component of lipoprotein (a) [<xref ref-type="bibr" rid="B3">3</xref>]. It is a highly polymorphic protein whose size varies depending on the number of Kringle IV type 2 (KIV) repeats [<xref ref-type="bibr" rid="B4">4</xref>]. Several polymorphisms of the APO (a) gene have been described in the 5'-untranslated region [<xref ref-type="bibr" rid="B5">5</xref>]. A pentanucleotide repeat (PNR) polymorphism (TTTTA)n located 1.3 kb upstream of the first exon in the APO (a) gene (chromosome 6, 6q26-q27) may explain a part of the between-individual variability of lipoprotein Lp(a) [<xref ref-type="bibr" rid="B6">6</xref>]. However, inconsistent results have been published concerning association of this polymorphism with CAD and/or MI [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>].</p><p>APO E gene, the most extensively studied polymorphism among apolipoproteins, has three common alleles designated E2, E3 and E4 coding for three protein isoforms (apo E2, apo E3 and apo E4, respectively) [<xref ref-type="bibr" rid="B9">9</xref>] that serve as a ligand for members of the low-density lipoprotein receptor (LDLR) family. This function is extremely important for the catabolism of triglyceride rich particles. It has been demonstrated that the E4 allele is associated with increased levels of plasma cholesterol, LDL-C, and increased risk for CAD [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>].</p><p>Apolipoproteins CI and CII are constituents of very low-density and high-density lipoproteins. The genes coding for these apolipoproteins are close to the APO E gene on the long arm of chromosome 19 (19 q<sub>13,2</sub>). The apo CI protein inhibits the bindings of beta very low-density and intermediary density lipoproteins to lipoproteins' receptors. Apo CII is required as a cofactor in the hydrolysis of triacylglycerides of chylomicrons and VLDL by lipoprotein lipase. Two restriction polymorphisms, the HincII site in the promoter region of the APO CI gene and the AvaII site in the intron 3 of the APO CII gene [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>], have been described in these proteins. The restriction site of APO CI has been associated with a significant increase of APO CI gene transcription [<xref ref-type="bibr" rid="B14">14</xref>]. Since these three genes are located in the same chromosome, the effect of the APO E, CI and CII gene cluster on serum lipid levels has been studied, particularly in Chinese Han samples of CAD patients [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. The results suggest that the linkage disequilibrium between APO E and APO CI should be, in part, responsible for the development of CAD.</p><p>In the present study we analyze the polymorphism of the four apolipoprotein genes [APO (a) PNR, APO E, APO CI and APO CII] in the Tunisian population and we check the relation of these polymorphisms and homocysteine, lipid and apolipoprotein levels to CAD.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Subjects</title><p>We conducted a hospital-based case study in 80 patients (80% men) with CAD complicated by MI (confirmed by ECG and coronary angiography) that were diagnosed and treated at the Department of Cardiology of the University Hospital Fattouma Bourguiba (Monastir, Tunisia). The mean age at diagnosis was 57.42 &#x000b1; 8.37 years. Among these patients, 56 were smokers; 51 had diabetes; 35 had hypertension and 22 were hyperlipidemic. As a control group, 100 individuals (76% men with age range close to that of the patient group), free of any CAD or any related disorders, were randomly selected from the same large geographical area to which belonged the patients (the center of Tunisia). Appropriate informed consent was obtained from patients and controls in accordance with the Ethical Committee Guidelines of the participating Hospital and University.</p></sec><sec><title>Plasma level measurements</title><p>Quantitative analyses of homocysteine, lipids and apolipoproteins were performed on only 50 controls and 50 patients within 24 h from collection. Plasma levels of total cholesterol (TC), triglycerides (TG) and HDL-cholesterol (HDL-C) were measured by an enzymatic colorimetric assay (using a clinical system, Beckman instruments). LDL-cholesterol concentrations were calculated by using the Friedewald formula [<xref ref-type="bibr" rid="B17">17</xref>]. Apolipoprotein (apo A-I, apo B, and apo E) concentrations were determined using an immunonephelometric assay on the nephelometer analyser II (Behring). The plasma concentrations of total homocysteine were measured by fluorescence polarization immunoassay on the AXSYM system.</p></sec><sec><title>DNA analysis</title><p>Leukocyte DNA was extracted from blood samples by phenol-chloroform method and amplified by PCR using oligonucleotide primers and amplification conditions described previously in [<xref ref-type="bibr" rid="B6">6</xref>] for the PNR of APO (a), APO E, APO CI, and APO CII polymorphisms [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. Alleles of the APO (a) PNR were identified by 10% polyacrylamide gel electrophoresis using DNA molecular weight markers. In the case of APO E, APO CI and APO CII, the PCR products were digested with Hha, HincII and AvaII enzymes, respectively and then separated by 10% polyacrylamide gel for APO E and APO CII and 2% agarose gel electrophoresis for APO CI.</p></sec><sec><title>Statistical analysis</title><p>Allelic and genotypic frequencies were calculated by direct gene counting method. The chi-square test was used to test Hardy-Weinberg equilibrium of all gene variants. Differences in frequencies between cases and controls were analyzed by Fisher's exact test. Haplotype calculations for the APO E-CI-CII gene cluster were done by means of the Arlequin v 2.0 package [<xref ref-type="bibr" rid="B19">19</xref>]. The same package was used to estimate the comparison between our Tunisian sample and other Mediterranean populations (exact test of population differentiation). Lipid and plasma parameter measures were compared through the student's t-test. The analysis of variance (ANOVA) was used to compare the mean lipid, lipoprotein and apolipoprotein levels associated with APO E genotypes.</p></sec></sec><sec><title>Results</title><p>Allele and genotype frequencies of the APO (a) PNR, APO E, APO CI and APO CII polymorphisms analyzed in controls and patients are presented in Table <xref ref-type="table" rid="T1">1</xref>. In all cases, genotype distributions were in Hardy-Weinberg equilibrium. APO E-APO CI-APO CII haplotypes are indicated in Table <xref ref-type="table" rid="T2">2</xref>.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Allele and genotype frequencies of APO (a) (PNR), APO E, APO CI and APO CII in control and CAD groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Allele</bold></td><td align="center" colspan="2"><bold>Allele frequencies</bold></td><td align="left"><bold>Genotype</bold></td><td align="center" colspan="2"><bold>Genotype Frequencies</bold></td></tr></thead><tbody><tr><td></td><td align="center">Control (N = 100)</td><td align="center">CAD (N = 80)</td><td></td><td align="center">Control (N = 100)</td><td align="center">CAD (N = 80)</td></tr><tr><td></td><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>APO (a)</bold></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">*7</td><td align="center">0.145</td><td align="center">0.168</td><td align="left">7/7</td><td align="center">0.020</td><td align="center">0.020</td></tr><tr><td align="left">*8</td><td align="center">0.645</td><td align="center">0.650</td><td align="left">7/8</td><td align="center">0.210</td><td align="center">0.240</td></tr><tr><td align="left">*9</td><td align="center">0.100</td><td align="center">0.037</td><td align="left">8/8</td><td align="center">0.430</td><td align="center">0.400</td></tr><tr><td align="left">*10</td><td align="center">0.045</td><td align="center">0.087</td><td align="left">8/9</td><td align="center">0.110</td><td align="center">0.040</td></tr><tr><td align="left">*11</td><td align="center">0.065</td><td align="center">0.056</td><td align="left">8/10</td><td align="center">0.040</td><td align="center">0.100</td></tr><tr><td></td><td></td><td></td><td align="left">8/11</td><td align="center">0.070</td><td align="center">0.120</td></tr><tr><td></td><td></td><td></td><td align="left">9/10</td><td align="center">0.020</td><td align="center">0.020</td></tr><tr><td></td><td></td><td></td><td align="left">Others</td><td align="center">0.100</td><td align="center">0.060</td></tr><tr><td align="left">P</td><td align="center" colspan="2">0.276</td><td></td><td align="center" colspan="2">0.182</td></tr><tr><td align="left"><bold>APO E</bold></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">*E2</td><td align="center">0.045</td><td align="center">0.037</td><td align="left">E2/E2</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left">*E3</td><td align="center">0.870</td><td align="center">0.876</td><td align="left">E2/E3</td><td align="center">0.080</td><td align="center">0.080</td></tr><tr><td align="left">*E4</td><td align="center">0.085</td><td align="center">0.087</td><td align="left">E2/E4</td><td align="center">0.010</td><td align="center">-</td></tr><tr><td></td><td></td><td></td><td align="left">E3/E3</td><td align="center">0.780</td><td align="center">0.760</td></tr><tr><td></td><td></td><td></td><td align="left">E3/E4</td><td align="center">0.130</td><td align="center">0.160</td></tr><tr><td></td><td></td><td></td><td align="left">E4/E4</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left">P</td><td align="center" colspan="2">0.917</td><td></td><td align="center" colspan="2">0.835</td></tr><tr><td align="left"><bold>APO CI</bold></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">*H1</td><td align="center">0.915</td><td align="center">0.893</td><td align="left">H1/H1</td><td align="center">0.830</td><td align="center">0.820</td></tr><tr><td align="left">*H2</td><td align="center">0.085</td><td align="center">0.107</td><td align="left">H1/H2</td><td align="center">0.170</td><td align="center">0.180</td></tr><tr><td align="left">P</td><td align="center" colspan="2">1</td><td></td><td align="center" colspan="2">1</td></tr><tr><td align="left"><bold>APO CII</bold></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">*A1</td><td align="center">0.555</td><td align="center">0.512</td><td align="left">A1/A1</td><td align="center">0.310</td><td align="center">0.320</td></tr><tr><td align="left">*A2</td><td align="center">0.445</td><td align="center">0.488</td><td align="left">A1/A2</td><td align="center">0.490</td><td align="center">0.400</td></tr><tr><td></td><td></td><td></td><td align="left">A2/A2</td><td align="center">0.200</td><td align="center">0.280</td></tr><tr><td align="left">P</td><td align="center" colspan="2">0.618</td><td></td><td align="center" colspan="2">0.635</td></tr></tbody></table><table-wrap-foot><p>Alleles (*H1, *A1) and (*H2, *A2) indicate absence and presence, respectively, of the enzyme restriction site.</p><p>P: Probability values for the comparison of allele and genotype frequencies between controls and CAD.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>APO E - CI - CII haplotype distribution in CAD and control subjects.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Haplotype</bold></td><td align="center"><bold>Control</bold></td><td align="center"><bold>CAD</bold></td></tr></thead><tbody><tr><td align="left"><bold>E2 - H1 - A1</bold></td><td align="center">0.0107</td><td align="center">-</td></tr><tr><td align="left"><bold>E2 - H1 - A2</bold></td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left"><bold>E2 - H2 - A1</bold></td><td align="center">0.0342</td><td align="center">0.0191</td></tr><tr><td align="left"><bold>E2 - H2 - A2</bold></td><td align="center">-</td><td align="center">0.0183</td></tr><tr><td></td><td></td><td></td></tr><tr><td align="left"><bold>E3 - H1 - A1</bold></td><td align="center">0.4155</td><td align="center">0.4107</td></tr><tr><td align="left"><bold>E3 - H1 - A2</bold></td><td align="center">0.4216</td><td align="center">0.4446</td></tr><tr><td align="left"><bold>E3 - H2 - A1</bold></td><td align="center">0.0167</td><td align="center">0.0196</td></tr><tr><td align="left"><bold>E3 - H2 - A2</bold></td><td align="center">0.0160</td><td align="center">-</td></tr><tr><td></td><td></td><td></td></tr><tr><td align="left"><bold>E4 - H1 - A1</bold></td><td align="center">0.0596</td><td align="center">0.03836</td></tr><tr><td align="left"><bold>E4 - H1 - A2</bold></td><td align="center">0.0072</td><td align="center">-</td></tr><tr><td align="left"><bold>E4 - H2 - A1</bold></td><td align="center">0.0180</td><td align="center">0.0247</td></tr><tr><td align="left"><bold>E4 - H2 - A2</bold></td><td align="center">-</td><td align="center">0.0244</td></tr><tr><td align="left"><bold>P</bold></td><td align="center">0.922</td><td></td></tr></tbody></table><table-wrap-foot><p>P: Probability values for the comparison of haplotype frequencies between controls and CAD.</p></table-wrap-foot></table-wrap><sec><title>Genetic profile of the Tunisian population</title><p>APO E allele frequencies of the present control sample from a wide area of the center of Tunisia are very close to those previously described in a Tunisian sample representative of the whole country (APO E2 = 4.5, APO E3 = 85.9, APO E4 = 9.5) [<xref ref-type="bibr" rid="B20">20</xref>]. The lack of significant differences between Tunisian samples reveals a high degree of population homogeneity when large geographic areas are considered. In addition, our control sample does not show any significant difference with other South European populations. Data on these populations and others are presented in a previous paper conducted by our research team [<xref ref-type="bibr" rid="B20">20</xref>].</p><p>Allele frequencies of APO (a), APO CI, and APO CII polymorphisms in the control Tunisian sample are compared with those found in other populations (Table <xref ref-type="table" rid="T3">3</xref>). Concerning APO (a) PNR, the allele of 8 repeats is the most common (0.635) in Tunisians agreeing with that observed in other South European populations [<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B24">24</xref>]. However, our sample exhibits some particular features such as the lowest and highest frequencies for the alleles of 10 and 7 repeats, respectively. As a result of this particular PNR allele distribution, pairwise population comparisons reveal remarkable significant differences (p &#x0003c; 0.01) between our Tunisian sample and the 6 South European groups recorded in Table <xref ref-type="table" rid="T3">3</xref>. Regarding the APO CI polymorphism, H1 is the most common allele with a frequency (0.915) similar to that found in several Spanish populations [<xref ref-type="bibr" rid="B21">21</xref>]. For the APO CII polymorphism, the frequencies of both alleles (0.555 for A1 and 0.445 for A2) are close to the pattern of variation observed in some Spanish groups [<xref ref-type="bibr" rid="B21">21</xref>]. No significant differences have been detected between Tunisians and Spaniards for these two gene polymorphisms.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Distribution of APO (a), APO CI, and APO CII in Tunisian population and others Mediterranean populations.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Population</bold></td><td align="center"><bold>N</bold></td><td align="center" colspan="7"><bold>Allele frequencies %</bold></td><td align="left"><bold>References</bold></td></tr></thead><tbody><tr><td align="left"><bold>APO (a)</bold></td><td></td><td align="center">*5</td><td align="center">*6</td><td align="center">*7</td><td align="center">*8</td><td align="center">*9</td><td align="center">*10</td><td align="center">*11</td><td></td></tr><tr><td align="left">Tunisia</td><td align="center">100</td><td align="center">0.0</td><td align="center">0.0</td><td align="center">14.5</td><td align="center">64.5</td><td align="center">10</td><td align="center">4.5</td><td align="center">6.5</td><td align="left">Present study</td></tr><tr><td align="left">Catalonia</td><td align="center">88</td><td align="center">0.0</td><td align="center">0.6</td><td align="center">0.6</td><td align="center">68.2</td><td align="center">14.2</td><td align="center">15.9</td><td align="center">0.6</td><td align="left">21</td></tr><tr><td align="left">Center Spain</td><td align="center">120</td><td align="center">0.0</td><td align="center">0.4</td><td align="center">0.4</td><td align="center">76.2</td><td align="center">12.9</td><td align="center">8.7</td><td align="center">1.3</td><td align="left">21</td></tr><tr><td align="left">Basque</td><td align="center">112</td><td align="center">0.0</td><td align="center">0.4</td><td align="center">0.4</td><td align="center">69.2</td><td align="center">18.3</td><td align="center">11.2</td><td align="center">0.4</td><td align="left">21</td></tr><tr><td align="left">France </td><td align="center">199</td><td align="center">0.2</td><td align="center">0.2</td><td align="center">1.0</td><td align="center">75.9</td><td align="center">10.5</td><td align="center">10.7</td><td align="center">1.5</td><td align="left">22</td></tr><tr><td align="left">Italy</td><td align="center">218</td><td align="center">0.0</td><td align="center">0.0</td><td align="center">1.1</td><td align="center">63.0</td><td align="center">17.0</td><td align="center">15.0</td><td align="center">3.9</td><td align="left">23</td></tr><tr><td align="left">Corsica </td><td align="center">47 </td><td align="center">0.0 </td><td align="center">0.0 </td><td align="center">0.0 </td><td align="center">77.7 </td><td align="center">6.4 </td><td align="center">14.9 </td><td align="center">1.1 </td><td align="left">24 </td></tr><tr><td align="left">Morocco (Berbers)</td><td align="center">138</td><td align="center">0.4</td><td align="center">0.0</td><td align="center">2.9</td><td align="center">63.8</td><td align="center">10.9</td><td align="center">11.6</td><td align="center">10.5</td><td align="left">25</td></tr><tr><td align="left"><bold>APO CI</bold></td><td></td><td align="center">*H1</td><td align="center">*H2</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Tunisia</td><td align="center">100</td><td align="center">91.5</td><td align="center">8.5</td><td></td><td></td><td></td><td></td><td></td><td align="left">Present study</td></tr><tr><td align="left">Catalonia</td><td align="center">88</td><td align="center">84.7</td><td align="center">15.3</td><td></td><td></td><td></td><td></td><td></td><td align="left">21</td></tr><tr><td align="left">Center Spain</td><td align="center">120</td><td align="center">85.4</td><td align="center">14.6</td><td></td><td></td><td></td><td></td><td></td><td align="left">21</td></tr><tr><td align="left">Basque</td><td align="center">111</td><td align="center">87.4</td><td align="center">12.6</td><td></td><td></td><td></td><td></td><td></td><td align="left">21</td></tr><tr><td align="left">Morocco (Berbers)</td><td align="center">120</td><td align="center">85.0</td><td align="center">15.0</td><td></td><td></td><td></td><td></td><td></td><td align="left">25</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>APOCII</bold></td><td></td><td align="center">*A1</td><td align="center">*A2</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Tunisia</td><td align="center">100</td><td align="center">55.5</td><td align="center">44.5</td><td></td><td></td><td></td><td></td><td></td><td align="left">Present study</td></tr><tr><td align="left">Catalonia</td><td align="center">88</td><td align="center">55.7</td><td align="center">44.3</td><td></td><td></td><td></td><td></td><td></td><td align="left">21</td></tr><tr><td align="left">Center Spain</td><td align="center">114</td><td align="center">48.7</td><td align="center">51.3</td><td></td><td></td><td></td><td></td><td></td><td align="left">21</td></tr><tr><td align="left">Basque</td><td align="center">112</td><td align="center">51.3</td><td align="center">48.7</td><td></td><td></td><td></td><td></td><td></td><td align="left">21</td></tr><tr><td align="left">Morocco (Berbers)</td><td align="center">117</td><td align="center">70.1</td><td align="center">29.9</td><td></td><td></td><td></td><td></td><td></td><td align="left">25</td></tr></tbody></table><table-wrap-foot><p>N: sample size.</p><p>Alleles (*H1, *A1) and (*H2, *A2) indicate absence and presence, respectively, of the enzyme restriction site.</p></table-wrap-foot></table-wrap><p>The pattern of allele variation in North Africa (Table <xref ref-type="table" rid="T3">3</xref>) is represented only by a Moroccan Berber group sample [<xref ref-type="bibr" rid="B25">25</xref>] of ethnically Berber communities dispersed and more and less isolated in the Middle Atlas mountainous region. No significant differences have been observed between our sample and this Berber group for the APO CI polymorphism. However, for both the APO (a) PNR and the APO CII polymorphisms we have found significant differences (p = 0.010 and p = 0.031, respectively). In fact, the relatively distinctive genetic features of this Berber group beside the general genetic profile of the North African populations as that of Tunisia suggests the influence of isolation events in its genetic background.</p></sec><sec><title>Comparative analyses between control and CAD groups</title><p>Lipid, lipoprotein and apolipoprotein mean concentrations are indicated in Table <xref ref-type="table" rid="T4">4</xref>. Compared to controls, CAD patients have significantly higher values of TC, TG (triglycerides), LDL-C, apo B and homocysteine, but significantly lower values of HDL-C, apo A-I and apo E. The increased apo B levels together with the decreased apo A-I levels contribute to increase the apo B/apo A-I ratio, a quotient commonly accepted as a risk factor for CAD.</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Lipid and apolipoprotein mean concentrations (&#x000b1; SD) in controls and CAD patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><bold>Control </bold>(N = 50)</td><td align="center"><bold>CAD </bold>(N = 50)</td><td align="center"><bold>P</bold></td></tr></thead><tbody><tr><td align="left"><bold>TC (mmol/L)</bold></td><td align="center">4.01 &#x000b1; 0.46</td><td align="center">4.62 &#x000b1; 0.9</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="left"><bold>TG (mmol/L)</bold></td><td align="center">0.78 &#x000b1; 1.78</td><td align="center">1.76 &#x000b1; 0.77</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="left"><bold>HDL-C (mmol/L)</bold></td><td align="center">1.07 &#x000b1; 0.12</td><td align="center">0.92 &#x000b1; 0.26</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="left"><bold>LDL-C (mmol/L)</bold></td><td align="center">2.57 &#x000b1; 0.44</td><td align="center">2.95 &#x000b1; 0.86</td><td align="center">&#x0003c;0.01</td></tr><tr><td align="left"><bold>Apo AI (g/L)</bold></td><td align="center">1.33 &#x000b1; 0.17</td><td align="center">1.04 &#x000b1; 0.13</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="left"><bold>Apo B (g/L)</bold></td><td align="center">0.76 &#x000b1; 0.18</td><td align="center">1.00 &#x000b1; 0.35</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="left"><bold>Apo E (mg/L)</bold></td><td align="center">50.24 &#x000b1; 7.63</td><td align="center">43.24 &#x000b1; 11.33</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="left"><bold>Apo B/ApoAI</bold></td><td align="center">0.59 &#x000b1; 0.16</td><td align="center">0.96 &#x000b1; 0.31</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="left"><bold>Homocysteine (&#x003bc;mol/L)</bold></td><td align="center">12.93 &#x000b1; 1.12</td><td align="center">16.6 &#x000b1; 4.58</td><td align="center">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><p>P: Student t-test probability for comparisons among Control and CAD groups.</p></table-wrap-foot></table-wrap><p>No significant differences have been detected between patients and controls neither for apolipoprotein gene frequencies (Table <xref ref-type="table" rid="T1">1</xref>) nor for the haplotype distribution (Table <xref ref-type="table" rid="T2">2</xref>) of the APO E-APO CI- APO CII gene cluster. Concerning this cluster, the linkage disequilibrium analysis showed a strong association (p &#x0003c; 0.0001) between APO E and APO CI in both groups and between APO E and APO CII only in controls (p = 0.008).</p><p>In spite of the lack of significant differences between patients and controls, several features are worth noting particularly at the level of APO E polymorphism. In the case of APO (a) PNR polymorphism, whereas the 8 repeats allele is found with similar frequencies in both groups, the frequency of the 9 repeats allele is higher in the control group. On the other hand, the 7 repeats allele frequency is higher in the CAD group.</p><p>As for APO E polymorphism, when the CAD sample is divided in two groups: hyperlipidemic (TC&#x0003e; 5.70 mmol/l) and non-hyperlipidemic subjects, the APO E4 allele is significantly (p &#x0003c; 0.05) higher in the hyperlipidemic patients (20.45% versus 3.51%, respectively). The same is true for the controls, although they all have normal TC concentrations (between 3 and 5 mmol/l) when controls are divided in two groups, a group with TC&#x0003c; 4 mmol/l and a second with TC&#x0003e; 4 mmol/l, the APO E4 allele is significantly (p &#x0003c; 0.05) higher in the second group (28.85% versus 8.33%, respectively).</p><p>Given this relation between the APO E polymorphism and the TC concentration, we have analyzed the influence of APO E genotypes on the distribution of all studied lipid, lipoprotein and apolipoprotein concentrations (Table <xref ref-type="table" rid="T5">5</xref>). In the patients and control groups, the subjects have been regrouped according to their E2/E3, E3/E3 or E3/E4 genotypes. The E2/E4 genotype is not considered, because it has been found in only three subjects of the control group. Both in patients and controls, we have compared individuals having E2 (E2/E3) with those having E4 (E4/E3). Those having E2 show significant low levels of TC, LDL-C and apo B, whereas those having E4 show significant high values of these parameters. Apo E concentrations are also affected by APO E genotypes in the two groups. E2 carriers show high significant concentration while E3/E3 genotypes have an intermediate value and E4 carriers show a significantly low value (Table <xref ref-type="table" rid="T5">5</xref>). Mean concentrations of other lipid parameters such as HDL-C, TG and apo A-I are not significantly different among the three APO E genotypes.</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Effect of APO E genotypes on plasma lipid and apolipoprotein profile in control and CAD groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Genotype</bold></td><td align="center"><bold>E2/E3 </bold>(6 controls, 4 CAD)</td><td align="center"><bold>E3/E3 </bold>(25 controls, 38 CAD)</td><td align="center"><bold>E3/E4 </bold>(16 controls, 8 CAD)</td><td align="center"><bold>P</bold></td></tr></thead><tbody><tr><td align="left">*<bold>TC</bold></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Controls</td><td align="center">3.48 &#x000b1; 0.35</td><td align="center">4.04 &#x000b1; 0.49</td><td align="center">4.20 &#x000b1; 0.35</td><td align="center">0.005</td></tr><tr><td align="left">&#x02003;CAD</td><td align="center">4.04 &#x000b1; 1.07</td><td align="center">4.58 &#x000b1; 0.62</td><td align="center">5.40 &#x000b1; 0.67</td><td align="center">0.007</td></tr><tr><td align="left">*<bold>TG</bold></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Controls</td><td align="center">0.88 &#x000b1; 0.10</td><td align="center">0.73 &#x000b1; 0.16</td><td align="center">0.83 &#x000b1; 0.19</td><td align="center">0.767</td></tr><tr><td align="left">&#x02003;CAD</td><td align="center">1.40 &#x000b1; 0.77</td><td align="center">1.74 &#x000b1; 0.70</td><td align="center">2.11 &#x000b1; 0.93</td><td align="center">0.314</td></tr><tr><td align="left">*<bold>HDL-C</bold></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Controls</td><td align="center">0.95 &#x000b1; 0.09</td><td align="center">1.12 &#x000b1; 0.09</td><td align="center">1.07 &#x000b1; 0.13</td><td align="center">0.074</td></tr><tr><td align="left">&#x02003;CAD</td><td align="center">0.86 &#x000b1; 0.39</td><td align="center">0.92 &#x000b1; 0.25</td><td align="center">0.93 &#x000b1; 0.28</td><td align="center">0.928</td></tr><tr><td align="left">*<bold>LDL-C</bold></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Controls</td><td align="center">2.12 &#x000b1; 0.38</td><td align="center">2.56 &#x000b1; 0.46</td><td align="center">2.75 &#x000b1; 0.38</td><td align="center">0.014</td></tr><tr><td align="left">&#x02003;CAD</td><td align="center">2.55 &#x000b1; 0.29</td><td align="center">2.82 &#x000b1; 0.70</td><td align="center">3.77 &#x000b1; 0.60</td><td align="center">0.017</td></tr><tr><td align="left">*<bold>Apo A-I</bold></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Controls</td><td align="center">1.33 &#x000b1; 0.29</td><td align="center">1.36 &#x000b1; 0.16</td><td align="center">1.27 &#x000b1; 0.13</td><td align="center">0.797</td></tr><tr><td align="left">&#x02003;CAD</td><td align="center">1.10 &#x000b1; 0.12</td><td align="center">1.03 &#x000b1; 0.14</td><td align="center">1.07 &#x000b1; 0.13</td><td align="center">0.939</td></tr><tr><td align="left">*<bold>Apo B</bold></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Controls</td><td align="center">0.61 &#x000b1; 0.06</td><td align="center">0.73 &#x000b1; 0.18</td><td align="center">0.85 &#x000b1; 0.16</td><td align="center">0.016</td></tr><tr><td align="left">&#x02003;CAD</td><td align="center">0.67 &#x000b1; 0.16</td><td align="center">0.98 &#x000b1; 0.36</td><td align="center">1.23 &#x000b1; 0.29</td><td align="center">0.038</td></tr><tr><td align="left">*<bold>Apo E</bold></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Controls</td><td align="center">57.00 &#x000b1; 6.07</td><td align="center">53.77 &#x000b1; 6.59</td><td align="center">44.62 &#x000b1; 5.40</td><td align="center">0.001</td></tr><tr><td align="left">&#x02003;CAD</td><td align="center">56.50 &#x000b1; 20.74</td><td align="center">42.65 &#x000b1; 9.90</td><td align="center">39.37 &#x000b1; 8.76</td><td align="center">0.043</td></tr></tbody></table><table-wrap-foot><p>Data is expressed as mean &#x000b1; SD; P: Probability values obtained by ANOVA for the comparison between E2/E3 and E3/E4 genotype groups.</p></table-wrap-foot></table-wrap><p>The severity of CAD in our sample has been estimated by the number (1, 2, or 3) of affected coronary vessels. Allele distributions of apolipoprotein gene polymorphisms in patients with 1, 2 and 3 affected vessels are shown in Table <xref ref-type="table" rid="T6">6</xref>. Allele distribution comparisons between patients with 1 and 3 affected vessels have shown a significant difference (p = 0.005) only for the APO E allele comparison. This fact suggests an association between APO E polymorphisms and CAD severity. In fact, the frequency of APO E4 increases whereas the frequencies of both APO E2 and APO E3 decrease with the increased number of affected vessels.</p><table-wrap position="float" id="T6"><label>Table 6</label><caption><p>Apolipoprotein allele frequencies and CAD severity.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Apolipoprotein alleles</bold></td><td align="center" colspan="6"><bold>CAD severity </bold>(N = 80)</td><td align="center"><bold>P</bold></td></tr></thead><tbody><tr><td></td><td align="center">1 vessel (n = 35)</td><td></td><td align="center">2 vessels (n = 31)</td><td></td><td align="center">3 vessels (n = 14)</td><td></td><td></td></tr><tr><td></td><td colspan="6"><hr></hr></td><td></td></tr><tr><td align="left"><bold>APO (a) alleles</bold></td><td align="center">n</td><td align="center">(%)</td><td align="center">n</td><td align="center">(%)</td><td align="center">n</td><td align="center">(%)</td><td align="center">0.121</td></tr><tr><td align="left">7</td><td align="center">13</td><td align="center">18.57</td><td align="center">11</td><td align="center">17.74</td><td align="center">3</td><td align="center">10.71</td><td></td></tr><tr><td align="left">8</td><td align="center">49</td><td align="center">70.00</td><td align="center">39</td><td align="center">62.9</td><td align="center">16</td><td align="center">57.14</td><td></td></tr><tr><td align="left">9</td><td align="center">2</td><td align="center">2.86</td><td align="center">4</td><td align="center">6.45</td><td align="center">0</td><td align="center">0.00</td><td></td></tr><tr><td align="left">10</td><td align="center">2</td><td align="center">2.86</td><td align="center">6</td><td align="center">9.68</td><td align="center">6</td><td align="center">21.42</td><td></td></tr><tr><td align="left">11</td><td align="center">4</td><td align="center">5.71</td><td align="center">2</td><td align="center">3.23</td><td align="center">3</td><td align="center">10.71</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>APOE alleles</bold></td><td align="center">n</td><td align="center">(%)</td><td align="center">n</td><td align="center">(%)</td><td align="center">n</td><td align="center">(%)</td><td align="center">0.005</td></tr><tr><td align="left">E2</td><td align="center">4</td><td align="center">5.71</td><td align="center">3</td><td align="center">4.84</td><td align="center">0</td><td align="center">0.00</td><td></td></tr><tr><td align="left">E3</td><td align="center">64</td><td align="center">91.42</td><td align="center">55</td><td align="center">88.7</td><td align="center">20</td><td align="center">71.43</td><td></td></tr><tr><td align="left">E4</td><td align="center">2</td><td align="center">2.85</td><td align="center">4</td><td align="center">6.45</td><td align="center">8</td><td align="center">28.57</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>APOCI alleles</bold></td><td align="center">n</td><td align="center">(%)</td><td align="center">n</td><td align="center">(%)</td><td align="center">n</td><td align="center">(%)</td><td align="center">0.285</td></tr><tr><td align="left">H1</td><td align="center">64</td><td align="center">91.42</td><td align="center">56</td><td align="center">90.32</td><td align="center">23</td><td align="center">82.14</td><td></td></tr><tr><td align="left">H2</td><td align="center">6</td><td align="center">8.57</td><td align="center">6</td><td align="center">9.68</td><td align="center">5</td><td align="center">17.85</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>APOCII alleles</bold></td><td align="center">n</td><td align="center">(%)</td><td align="center">n</td><td align="center">(%)</td><td align="center">n</td><td align="center">(%)</td><td align="center">1</td></tr><tr><td align="left">A1</td><td align="center">33</td><td align="center">47.14</td><td align="center">36</td><td align="center">58.07</td><td align="center">13</td><td align="center">46.42</td><td></td></tr><tr><td align="left">A2</td><td align="center">37</td><td align="center">52.85</td><td align="center">26</td><td align="center">41.93</td><td align="center">15</td><td align="center">53.57</td><td></td></tr></tbody></table><table-wrap-foot><p>P: probability values for the comparison of allele distribution between patients with 1 and 3 affected vessels.</p></table-wrap-foot></table-wrap></sec></sec><sec><title>Discussion</title><p>In this study we have analyzed for the first time the polymorphisms of APO (a) PNR, APO E, APO CI and APO CII genes together with several lipid and apolipoprotein levels in Tunisian CAD patients and in controls. This constitutes an approach to the genetic characterization of the lipid profiles of Tunisian cardiovascular patients and supplies anthropological data on the Tunisian population.</p><p>Although APO (a) PNR, APO CI and APO CII gene polymorphisms have been analyzed in only few populations from South Europe (Table <xref ref-type="table" rid="T2">2</xref>), they show frequency distribution between Mediterranean populations similar to that found according to APO E gene and other widely analyzed genetic markers [for review see [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B26">26</xref>-<xref ref-type="bibr" rid="B28">28</xref>]]. In fact, we have found modest significant differences among our Tunisian sample and those of South Europe only for the APO (a) PNR distribution. Thus, populations of the two Mediterranean shores share a relative genetic homogeneity that probably reflects a common origin and/or remarkable levels of gene flow.</p><p>Comparative analyses between control and CAD groups from Tunisia have shown important observations, particularly in comparison with those found in other populations. Concerning the analyses of plasma lipid mean concentrations, the significant high values of TC, LDL-C, apo B and TG, and the significant low values of HDL-C, apo A-I, and apo E shown by Tunisian patients with CAD have been also observed in other populations [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. The homocysteine concentration, that shows mean values around 28.4% higher in CAD Tunisian patients than in controls, presents a linear relationship with the severity of CAD (14.67 &#x003bc;mol/L, 17.46 &#x003bc;mol/L, and 18.7 &#x003bc;mol/L for 1, 2 and 3 affected vessels respectively, p &#x0003c; 0.05). This relationship suggests that high homocysteine levels are associated with CAD and with its severity. Similar observations have been found in Iranian and Greek populations [<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>] but not demonstrated in a sample of American population [<xref ref-type="bibr" rid="B33">33</xref>]. It will be interesting to check this association in other populations and to add the quantification of homocysteine to the classic parameters analyzed in the routine practice.</p><p>In the case of the APO CI and APO CII polymorphisms, no association was noted with CAD. In fact, only few studies have analyzed the association of these polymorphisms with the disease. In a study on the Chinese population [<xref ref-type="bibr" rid="B16">16</xref>] the authors found that only APO CI polymorphism was associated with CAD.</p><p>Regarding the APO (a) PNR polymorphism, we ascertained a global negative association between the number of TTTTA repeats and CAD. This agrees with conclusions relating to Russian, French and Irish populations [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B34">34</xref>]. However, general associations between "short" TTTTA repeats (less than 10 repeats) and MI or CAD have been reported in other populations [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. In addition, in this study we have noted that when the allele distribution is considered in relation to the severity of the disease (Table <xref ref-type="table" rid="T6">6</xref>) a trend, although not significant, appears towards an increase of larger (&#x02265; 10 repeats) alleles in the subgroup with major severity. While, in a previous study on the Japanese population, the authors showed that the homozygous genotype for the "short" 8 repeats allele was related to the number of diseased vessels [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>The differences in results on CAD risk noted between populations probably reflect the complexity of the involvement of many genetic and environmental factors in CAD appearance. In fact, these risk factors are probably candidate factors and the appearance of the CAD does not need the presence of all of them. Namely, in a given population the presence of only some (effecter factor group) of these candidate factors, are enough for favoring the CAD appearance without or with slight secondary influence of the other factors. The effecter factor group is very likely the result of a complex gene-environmental interaction, which can vary from a population to another. Our observations relating to APO E polymorphism may illustrate this proposal.</p><p>In some populations (Italian, Turk and Iranian) a significantly higher frequency of APO E4 allele was observed in CAD patients compared with healthy subjects [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B37">37</xref>]. Thus, APO E4 allele can be considered among candidate risk factors for CAD. However, in our Tunisian population as in Kuwaiti, Polish and Finnish populations [<xref ref-type="bibr" rid="B38">38</xref>-<xref ref-type="bibr" rid="B40">40</xref>] no significantly higher frequency of APO E4 allele has been found in CAD patients. Namely, in these populations APO E4 allele is not among effecter factor group and it is without or with slight secondary influence on the appearance of CAD. In fact, this slight secondary influence is shown both in the Tunisian and the Finnish [<xref ref-type="bibr" rid="B40">40</xref>] populations by an association between the APO E4 allele and the CAD severity.</p><p>The study of the impact of APO E genotype variations on serum lipid parameters shows that CAD patients and healthy subjects with APO E4 allele have higher levels of atherogenic parameters (TC, LDL-C and apo B), whereas subjects with APO E2 allele have low levels of these parameters. Such APO E allele effects have been also noted in some other populations [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. The impact of APO E allelic variation in the TC, LDL-C and apo B levels is mainly due to up and down regulation of LDL receptors by the E2 and E4 alleles respectively [<xref ref-type="bibr" rid="B41">41</xref>].</p><p>The effect of APO E4 on CAD severity could be the consequence of its association to significant high levels of atherogenic parameters and its association to low levels of apo E. In fact, the significant low mean concentration of apo E in CAD patients, observed also in the Italian population [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B30">30</xref>] suggests that apo E plays an anti-atherogenic role.</p><p>The effect of APO E genotypes on HDL-C concentration has not demonstrated the same consistency across populations. In the present study, no association has been found between APO E polymorphism and HDL-C concentrations in both patient and control groups. The relation of APO E polymorphism and HDL-C has been reported in some populations [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B42">42</xref>] but not in others [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B43">43</xref>]. These differences between populations can be explained by gene-environmental interaction. Indeed, HDL-C levels are affected by exercise and alcohol consumption [<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B45">45</xref>].</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>RB performed all the experiments and data analyses and contributed in the interpretation of results and in the editing of the manuscript, EE performed a direct help and supervision of all DNA analyses and contributed in data analyses and in the review of the manuscript, PM performed a general supervision of all DNA analyses and data analyses and participated in the review of the manuscript, MH participated in control's group collection, KBH participated in coronary artery disease patient collection, HC supervised all the work and participated in the result interpretations and in the editing and the review of the manuscript. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We gratefully acknowledge blood donors. We thank Pr. Abdelhedi Miled and his colleagues in the department of Biochemistry and toxicology at University Hospital of Sousse (Tunisia) for their encouragement and generous help.</p><p>This research was supported in part by the <italic>Agencia Espa&#x000f1;ola de Cooperaci&#x000f3;n </italic>(Tunis-Spain)<italic>Internacional </italic>28/04/P and A/4850/06 projects, the Ministerio de Ciencia y Tecnologia CGL 2005-3391 and Generalitat de Catalunya 2005SGR00252 grants, and a grant from the Tunisian Ministry of Higher Education within the research unity 05/UR/09-04.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Sacks</surname><given-names>FM</given-names></name><name><surname>Salvini</surname><given-names>S</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name></person-group><article-title>A prospective study of cholesterol, apolipoproteins and the risk of Myocardial infarction</article-title><source>N Engl J Med</source><year>1991</year><volume>325</volume><fpage>373</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">2062328</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brenn</surname><given-names>T</given-names></name></person-group><article-title>Genetic environmental effects on coronary heart disease risk factors in northern Norway. The cardiovascular disease study in Finn mark</article-title><source>Ann Hum Genet</source><year>1994</year><volume>58</volume><fpage>369</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">7864592</pub-id><pub-id pub-id-type="doi">10.1111/j.1469-1809.1994.tb00733.x</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaubatz</surname><given-names>JW</given-names></name><name><surname>Heideman</surname><given-names>C</given-names></name><name><surname>Gotto</surname><given-names>AM</given-names></name><name><surname>Morrisett</surname><given-names>JD</given-names></name><name><surname>Dahlen</surname><given-names>GH</given-names></name></person-group><article-title>Human plasma lipoprotein (a): Structural properties</article-title><source>J Biol Chem</source><year>1983</year><volume>258</volume><fpage>4582</fpage><lpage>4589</lpage><pub-id pub-id-type="pmid">6220008</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lackner</surname><given-names>C</given-names></name><name><surname>Cohen</surname><given-names>JC</given-names></name><name><surname>Hobbs</surname><given-names>H</given-names></name></person-group><article-title>Molecular definition of the extern size polymorphism in apolipoprotein (a)</article-title><source>Hum Mol Genet</source><year>1993</year><volume>2</volume><fpage>933</fpage><lpage>940</lpage><pub-id pub-id-type="pmid">8395942</pub-id><pub-id pub-id-type="doi">10.1093/hmg/2.7.933</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wade</surname><given-names>DP</given-names></name><name><surname>Clarke</surname><given-names>JG</given-names></name><name><surname>Lindahl</surname><given-names>GE</given-names></name><name><surname>Liu</surname><given-names>AC</given-names></name><name><surname>Azysow</surname><given-names>BR</given-names></name><name><surname>Meer</surname><given-names>K</given-names></name><name><surname>Schwartz</surname><given-names>K</given-names></name><name><surname>Lawn</surname><given-names>RM</given-names></name></person-group><article-title>5' control regions of the apolipoprotein (a) gene and members of the related plasminogen gene family</article-title><source>Proc Natl Acad Sci USA</source><year>1993</year><volume>90</volume><fpage>1969</fpage><lpage>1973</lpage><pub-id pub-id-type="doi">10.1073/pnas.90.4.1369</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trommsdorff</surname><given-names>M</given-names></name><name><surname>K&#x000f6;chl</surname><given-names>S</given-names></name><name><surname>Lingenhel</surname><given-names>A</given-names></name><name><surname>Kronenberg</surname><given-names>F</given-names></name><name><surname>Delport</surname><given-names>R</given-names></name><name><surname>Vermaak</surname><given-names>H</given-names></name><name><surname>Lemming</surname><given-names>L</given-names></name><name><surname>Klausen</surname><given-names>IC</given-names></name><name><surname>Faergeman</surname><given-names>O</given-names></name><name><surname>Utermann</surname><given-names>G</given-names></name><name><surname>Kraft</surname><given-names>HG</given-names></name></person-group><article-title>A pentanucleotide repeat polymorphism in the 5'-control region of the apolipoprotein (a) gene is associated with lipoprotein (a) plasma concentrations in Caucasians</article-title><source>J Clin Invest</source><year>1995</year><volume>96</volume><fpage>150</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">7615785</pub-id><pub-id pub-id-type="doi">10.1172/JCI118015</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amemiya</surname><given-names>H</given-names></name><name><surname>Arinami</surname><given-names>T</given-names></name><name><surname>Kikuchi</surname><given-names>S</given-names></name><name><surname>Yamakawa-Kobayashi</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Fujiwara</surname><given-names>H</given-names></name><name><surname>Hiroe</surname><given-names>M</given-names></name><name><surname>Marumo</surname><given-names>F</given-names></name><name><surname>Hamaguchi</surname><given-names>H</given-names></name></person-group><article-title>Apolipoprotein (a) size and pentanucleotide repeat polymorphisms are associated with the degree of atherosclerosis in coronary heart disease</article-title><source>Atherosclerosis</source><year>1996</year><volume>123</volume><fpage>181</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">8782849</pub-id><pub-id pub-id-type="doi">10.1016/0021-9150(96)05806-6</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Volkova</surname><given-names>MV</given-names></name><name><surname>Vasina</surname><given-names>VI</given-names></name><name><surname>Fomicheva</surname><given-names>EV</given-names></name><name><surname>Shwartz</surname><given-names>EI</given-names></name></person-group><article-title>Comparative analysis of apo (a) gene alleles Distribution of pentanucleotide repeats in position -1373 and C/T transition in position (+93) among patients with myocardial infarction and a control group in St Petersburg, Russia</article-title><source>Biochem Mol Med</source><year>1997</year><volume>61</volume><fpage>208</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">9259986</pub-id><pub-id pub-id-type="doi">10.1006/bmme.1997.2582</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahley</surname><given-names>RW</given-names></name><name><surname>Rall</surname><given-names>SC</given-names></name></person-group><article-title>Apolipoprotein E: Far more than a lipid transport protein</article-title><source>Annu Rev Genomics Hum Genet</source><year>2000</year><volume>1</volume><fpage>507</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">11701639</pub-id><pub-id pub-id-type="doi">10.1146/annurev.genom.1.1.507</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corbo</surname><given-names>RM</given-names></name><name><surname>Vilardo</surname><given-names>T</given-names></name><name><surname>Ruggeri</surname><given-names>M</given-names></name><name><surname>Gemma</surname><given-names>AT</given-names></name><name><surname>Scacchi</surname><given-names>R</given-names></name></person-group><article-title>Apolipoprotein E genotype and plasma levels in coronary artery disease: A case-control study in the Italian population</article-title><source>Clin Biochem</source><year>1999</year><volume>32</volume><fpage>217</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">10383084</pub-id><pub-id pub-id-type="doi">10.1016/S0009-9120(99)00011-9</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Isbir</surname><given-names>T</given-names></name><name><surname>Yilmaz</surname><given-names>H</given-names></name><name><surname>Agachan</surname><given-names>B</given-names></name><name><surname>Karaali</surname><given-names>ZE</given-names></name></person-group><article-title>Cholesterol Ester transfer protein, apolipoprotein E and lipoprotein lipase genotypes in patients with coronary artery disease in the Turkish population</article-title><source>Clin Genet</source><year>2003</year><volume>64</volume><fpage>228</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">12919138</pub-id><pub-id pub-id-type="doi">10.1034/j.1399-0004.2003.00137.x</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nillesen</surname><given-names>WM</given-names></name><name><surname>Smeets</surname><given-names>HJM</given-names></name><name><surname>Van</surname><given-names>OBA</given-names></name></person-group><article-title>Human ApoCI HpaI restriction site polymorphism revealed by the polymerase chain reaction</article-title><source>Nucleic Acids Res</source><year>1990</year><volume>18</volume><fpage>3428</fpage><pub-id pub-id-type="pmid">1972565</pub-id><pub-id pub-id-type="doi">10.1093/nar/18.11.3428-a</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geisel</surname><given-names>J</given-names></name><name><surname>Weibhaar</surname><given-names>C</given-names></name><name><surname>Oette</surname><given-names>K</given-names></name></person-group><article-title>An AvaII polymorphism in the human apolipoprotein CII</article-title><source>Clin Genet</source><year>1996</year><volume>49</volume><fpage>163</fpage><pub-id pub-id-type="pmid">8737984</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Berglund</surname><given-names>L</given-names></name><name><surname>Ramakrishnan</surname><given-names>R</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name><name><surname>Ngai</surname><given-names>C</given-names></name><name><surname>Holleran</surname><given-names>S</given-names></name><name><surname>Tycko</surname><given-names>B</given-names></name><name><surname>Leff</surname><given-names>T</given-names></name><name><surname>Schachter</surname><given-names>S</given-names></name></person-group><article-title>A common HpaI/RFLP of apolipoprotein C-I increases gene transcription and exhibits an ethnically distinct pattern of linkage disequilibrium with the alleles of apolipoprotein E</article-title><source>J Lipid Res</source><year>1999</year><volume>40</volume><fpage>50</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">9869649</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>D</given-names></name><name><surname>Tan</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>F</given-names></name><name><surname>Shi</surname><given-names>Q</given-names></name></person-group><article-title>Combined effects of apoE-CI-CII cluster and LDL-R gene polymorphisms on chromosome 19 and coronary artery disease risk</article-title><source>Int J Hyg Environ Health</source><year>2006</year><volume>209</volume><fpage>265</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">16459141</pub-id><pub-id pub-id-type="doi">10.1016/j.ijheh.2005.12.005</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whang</surname><given-names>CH</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>Q</given-names></name><name><surname>Zheng</surname><given-names>F</given-names></name></person-group><article-title>Apolipoprotein E-CI-CII gene cluster and its effect on serum lipid levels</article-title><source>Wei Sheng Yan Jiu</source><year>2005</year><volume>34</volume><fpage>104</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">15862040</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedewald</surname><given-names>WT</given-names></name><name><surname>Levy</surname><given-names>RI</given-names></name><name><surname>Fredrickson</surname><given-names>DS</given-names></name></person-group><article-title>Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge</article-title><source>Clin Chem</source><year>1972</year><volume>18</volume><fpage>499</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">4337382</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>MS</given-names></name><name><surname>Tangalos</surname><given-names>EG</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Smith</surname><given-names>GE</given-names></name><name><surname>Schaid</surname><given-names>DJ</given-names></name><name><surname>Kokmen</surname><given-names>E</given-names></name><name><surname>Ivnik</surname><given-names>RJ</given-names></name><name><surname>Thibodeau</surname><given-names>SN</given-names></name></person-group><article-title>Apolipoprotein E: risk factor for Alzheimer disease</article-title><source>Am J Hum Genet</source><year>1994</year><volume>54</volume><fpage>643</fpage><lpage>649</lpage><pub-id pub-id-type="pmid">8128961</pub-id></citation></ref><ref id="B19"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>S</given-names></name><name><surname>Roessli</surname><given-names>D</given-names></name><name><surname>Excoffier</surname><given-names>L</given-names></name></person-group><source>Arlequin: software for population genetics data analysis</source><year>2000</year><publisher-name>Ver. 2.0 Geneva, Switzerland: Genetics and Biometry Laboratory, Department of Anthropology and Ecology, University of Geneva</publisher-name></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bahri</surname><given-names>R</given-names></name><name><surname>Esteban</surname><given-names>E</given-names></name><name><surname>Moral</surname><given-names>P</given-names></name><name><surname>Chaabani</surname><given-names>H</given-names></name></person-group><article-title>New insights into the genetic history of Tunisians: Data from Alu insertion and apolipoprotein E gene polymorphisms</article-title><source>Ann Hum Biol</source><year>2008</year><volume>35</volume><fpage>22</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">18274923</pub-id><pub-id pub-id-type="doi">10.1080/03014460701753729</pub-id></citation></ref><ref id="B21"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Valveny</surname><given-names>N</given-names></name></person-group><article-title>Factors de risc genetics per a la Cardiopatia isqu&#x000e8;mica Polimorfismes en genes del metabolisme lipoproteic</article-title><source>PhD thesis</source><year>2000</year><publisher-name>University of Barcelona, Barcelona</publisher-name></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valenti</surname><given-names>K</given-names></name><name><surname>Aveynier</surname><given-names>E</given-names></name><name><surname>Leaut&#x000e9;</surname><given-names>S</given-names></name><name><surname>Laporte</surname><given-names>F</given-names></name><name><surname>Hadjian</surname><given-names>AJ</given-names></name></person-group><article-title>Contribution of apolipoprotein(a) size, pentanucleotide TTTTA repeat and C/T (+93) polymorphisms of the apo(a) gene to regulation of lipoprotein(a) plasma levels in a population of young European Caucasians</article-title><source>Atherosclerosis</source><year>1999</year><volume>147</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">10525120</pub-id><pub-id pub-id-type="doi">10.1016/S0021-9150(99)00137-9</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chimienti</surname><given-names>G</given-names></name><name><surname>Lamanuzzi</surname><given-names>BL</given-names></name><name><surname>Nardulli</surname><given-names>M</given-names></name><name><surname>Colacicco</surname><given-names>AM</given-names></name></person-group><article-title>Apo(a) Variants and Lipoprotein(a) in Men with or without Myocardial infarction</article-title><source>Exp Mol Pathol</source><year>2002</year><volume>73</volume><fpage>28</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">12127051</pub-id><pub-id pub-id-type="doi">10.1006/exmp.2002.2445</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calo</surname><given-names>CM</given-names></name><name><surname>Varesi</surname><given-names>L</given-names></name><name><surname>Memmi</surname><given-names>M</given-names></name><name><surname>Moral</surname><given-names>P</given-names></name><name><surname>Vona</surname><given-names>G</given-names></name></person-group><article-title>A pentanucleotide repeat polymorphism (TTTTA) in the apolipoprotein (a) gene-Its distribution and its association with the risk of cardiovascular disease</article-title><source>Coll Antropol</source><year>2003</year><volume>27</volume><fpage>105</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">12974138</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harich</surname><given-names>N</given-names></name><name><surname>Esteban</surname><given-names>E</given-names></name><name><surname>Lopez-Alomar</surname><given-names>A</given-names></name><name><surname>Chafik</surname><given-names>A</given-names></name><name><surname>Moral</surname><given-names>P</given-names></name></person-group><article-title>Apolipoprotein molecular variation in Moroccan Berbers: pentanucleotide (TTTTA) n repeat in the LPA gene and APOE-C1-C2 gene cluster</article-title><source>Clin Genet</source><year>2002</year><volume>62</volume><fpage>240</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">12220441</pub-id><pub-id pub-id-type="doi">10.1034/j.1399-0004.2002.620310.x</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaabani</surname><given-names>H</given-names></name></person-group><article-title>GM polymorphisms and the evolutionary history of modern humans</article-title><source>Annales de g&#x000e9;n&#x000e9;tique</source><year>2002</year><volume>45</volume><fpage>197</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/S0003-3995(02)01140-1</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coudray</surname><given-names>C</given-names></name><name><surname>Guitard</surname><given-names>E</given-names></name><name><surname>Kandil</surname><given-names>M</given-names></name><name><surname>Harich</surname><given-names>N</given-names></name><name><surname>Melhaoui</surname><given-names>M</given-names></name><name><surname>Baali</surname><given-names>A</given-names></name><name><surname>Seven</surname><given-names>A</given-names></name><name><surname>Moral</surname><given-names>P</given-names></name><name><surname>Dugoujon</surname><given-names>JM</given-names></name></person-group><article-title>Study of GM Immunoglobulin Allotypic System in Berbers and Arabs from Morocco</article-title><source>Am J Hum Biol</source><year>2006</year><volume>18</volume><fpage>23</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">16378347</pub-id><pub-id pub-id-type="doi">10.1002/ajhb.20465</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moral</surname><given-names>P</given-names></name><name><surname>Valveny</surname><given-names>N</given-names></name><name><surname>Lopez-Alomar</surname><given-names>A</given-names></name><name><surname>Calo</surname><given-names>C</given-names></name><name><surname>Kandil</surname><given-names>M</given-names></name><name><surname>Harich</surname><given-names>N</given-names></name><name><surname>Gonzalez-Perez</surname><given-names>E</given-names></name><name><surname>Via</surname><given-names>M</given-names></name><name><surname>Esteban</surname><given-names>E</given-names></name><name><surname>Dugoujon</surname><given-names>JM</given-names></name><name><surname>Vona</surname><given-names>G</given-names></name></person-group><article-title>Molecular variation at genes and the history of human populations-Data on candidate genes for cardiovascular risk in the Mediterranean</article-title><source>Coll Antropol</source><year>2003</year><volume>27</volume><fpage>523</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">14746139</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elisaf</surname><given-names>MS</given-names></name><name><surname>Siamopoulos</surname><given-names>KC</given-names></name><name><surname>Tselegarides</surname><given-names>TJ</given-names></name><name><surname>Bairaktari</surname><given-names>ETh</given-names></name><name><surname>Goudevenos</surname><given-names>JA</given-names></name><name><surname>Tselepis</surname><given-names>AD</given-names></name><name><surname>Tsolas</surname><given-names>OE</given-names></name><name><surname>Sideris</surname><given-names>DA</given-names></name></person-group><article-title>Lipid abnormalities in Greek patients with coronary artery disease</article-title><source>Int J Card</source><year>1997</year><volume>59</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/S0167-5273(96)02916-6</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baroni</surname><given-names>MG</given-names></name><name><surname>Berni</surname><given-names>A</given-names></name><name><surname>Romeo</surname><given-names>S</given-names></name><name><surname>Arca</surname><given-names>M</given-names></name><name><surname>Tesorio</surname><given-names>T</given-names></name><name><surname>Sorropago</surname><given-names>G</given-names></name><name><surname>Di Mario</surname><given-names>U</given-names></name><name><surname>Galton</surname><given-names>DJ</given-names></name></person-group><article-title>Genetic study of common variants at the Apo E, Apo AI, Apo CIII, Apo B, lipoprotein lipase (LPL) and hepatic lipase (LIPC) genes and coronary artery disease (CAD): variation in LIPC gene associates with clinical outcomes in patients with established CAD</article-title><source>BMC Med Genet</source><year>2003</year><volume>4</volume><fpage>8</fpage><pub-id pub-id-type="pmid">12964943</pub-id><pub-id pub-id-type="doi">10.1186/1471-2350-4-8</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kazemi</surname><given-names>MB</given-names></name><name><surname>Eshraghian</surname><given-names>K</given-names></name><name><surname>Omrani</surname><given-names>GR</given-names></name><name><surname>Lankarani</surname><given-names>KB</given-names></name><name><surname>Hosseini</surname><given-names>E</given-names></name></person-group><article-title>Homocysteine level and coronary artery disease</article-title><source>Angiology</source><year>2006</year><volume>57</volume><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">16444451</pub-id><pub-id pub-id-type="doi">10.1177/000331970605700102</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vrentzos</surname><given-names>G</given-names></name><name><surname>Papadakis</surname><given-names>JA</given-names></name><name><surname>Malliaraki</surname><given-names>N</given-names></name><name><surname>Zacharis</surname><given-names>EA</given-names></name><name><surname>Katsogridakis</surname><given-names>K</given-names></name><name><surname>Margioris</surname><given-names>AN</given-names></name><name><surname>Vardas</surname><given-names>PE</given-names></name><name><surname>Ganotakis</surname><given-names>ES</given-names></name></person-group><article-title>Association of serum total homocysteine with the extent of ischemic heart disease in a Mediterranean cohort</article-title><source>Angiology</source><year>2004</year><volume>55</volume><fpage>517</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">15378114</pub-id><pub-id pub-id-type="doi">10.1177/000331970405500507</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>SS</given-names></name><name><surname>Passen</surname><given-names>EL</given-names></name><name><surname>Ruggie</surname><given-names>N</given-names></name><name><surname>Wong</surname><given-names>PW</given-names></name><name><surname>Sora</surname><given-names>H</given-names></name></person-group><article-title>Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease</article-title><source>Circulation</source><year>1993</year><volume>88</volume><fpage>1463</fpage><lpage>1469</lpage><pub-id pub-id-type="pmid">8403293</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brazier</surname><given-names>L</given-names></name><name><surname>Tiret</surname><given-names>L</given-names></name><name><surname>Luc</surname><given-names>G</given-names></name><name><surname>Arvelier</surname><given-names>D</given-names></name><name><surname>Ruidavets</surname><given-names>JB</given-names></name><name><surname>Evans</surname><given-names>A</given-names></name><name><surname>Chapman</surname><given-names>J</given-names></name><name><surname>Cambien</surname><given-names>F</given-names></name><name><surname>Thillet</surname><given-names>J</given-names></name></person-group><article-title>Sequence polymorphisms in the apolipoprotein (a) gene and their association with lipoprotein (a) level and myocardial infarction. The ECTIM Study</article-title><source>Atherosclerosis</source><year>1999</year><volume>144</volume><fpage>323</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">10407493</pub-id><pub-id pub-id-type="doi">10.1016/S0021-9150(98)00333-5</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benes</surname><given-names>P</given-names></name><name><surname>Muzik</surname><given-names>J</given-names></name><name><surname>Benedik</surname><given-names>J</given-names></name><name><surname>Frelich</surname><given-names>M</given-names></name><name><surname>Elbl</surname><given-names>L</given-names></name><name><surname>Vasku</surname><given-names>A</given-names></name><name><surname>Znojil</surname><given-names>V</given-names></name><name><surname>Vacha</surname><given-names>J</given-names></name></person-group><article-title>Single effects of apolipoprotein B, (a) and E polymorphisms and interaction between plasminogen activator inhibitor-1 and apolipoprotein (a) genotypes and the risk of coronary artery disease in Czech male Caucasians</article-title><source>Mol Genet Metab</source><year>2000</year><volume>69</volume><fpage>137</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">10720441</pub-id><pub-id pub-id-type="doi">10.1006/mgme.1999.2957</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kalina</surname><given-names>A</given-names></name><name><surname>Csaszar</surname><given-names>A</given-names></name><name><surname>F&#x000fc;st</surname><given-names>G</given-names></name><name><surname>Nagy</surname><given-names>B</given-names></name><name><surname>Szalai</surname><given-names>C</given-names></name><name><surname>Karadi</surname><given-names>I</given-names></name><name><surname>Duba</surname><given-names>J</given-names></name><name><surname>Prohaszka</surname><given-names>Z</given-names></name><name><surname>Horvath</surname><given-names>L</given-names></name><name><surname>Dieplinger</surname><given-names>H</given-names></name></person-group><article-title>The association of serum lipoprotein (a) levels, apolipoprotein(a) size and (TTTTA)n polymorphism with coronary heart disease</article-title><source>Clin Chim Acta</source><year>2001</year><volume>309</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">11408005</pub-id><pub-id pub-id-type="doi">10.1016/S0009-8981(01)00500-9</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kharrazi</surname><given-names>H</given-names></name><name><surname>Vaisi</surname><given-names>RA</given-names></name><name><surname>Sabokroh</surname><given-names>AR</given-names></name><name><surname>Pourmotabbed</surname><given-names>T</given-names></name></person-group><article-title>Association between apolipoprotein E polymorphism and coronary artery disease in the Kermanshah population in Iran</article-title><source>Clin Biochem</source><year>2006</year><volume>39</volume><fpage>613</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">16545358</pub-id><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2006.02.002</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akanji</surname><given-names>AO</given-names></name><name><surname>Suresh</surname><given-names>CG</given-names></name><name><surname>Fatania</surname><given-names>HR</given-names></name><name><surname>Al-Radwan</surname><given-names>R</given-names></name><name><surname>Zubaid</surname><given-names>M</given-names></name></person-group><article-title>Associations of apolipoprotein E polymorphism with low-density lipoprotein size and subfraction profiles in arab patients with coronary artery disease</article-title><source>Metabolism</source><year>2007</year><volume>56</volume><fpage>484</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">17379005</pub-id><pub-id pub-id-type="doi">10.1016/j.metabol.2006.11.006</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zak</surname><given-names>I</given-names></name><name><surname>Balcerzyk</surname><given-names>A</given-names></name><name><surname>Sarecka</surname><given-names>B</given-names></name><name><surname>Niemiec</surname><given-names>P</given-names></name><name><surname>Ciemniewski</surname><given-names>Z</given-names></name><name><surname>Dylag</surname><given-names>S</given-names></name></person-group><article-title>Contemporaneous carrier-state of two or three "proatherosclerotic" variants of APOE, ICAM1, PPARA and PAI-1 genes differentiate CAD patients from healthy individuals</article-title><source>Clin Chim Acta</source><year>2005</year><volume>362</volume><fpage>110</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">16043164</pub-id><pub-id pub-id-type="doi">10.1016/j.cccn.2005.06.011</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lehtinen</surname><given-names>S</given-names></name><name><surname>Lehtim&#x000e4;ki</surname><given-names>T</given-names></name><name><surname>Sisto</surname><given-names>T</given-names></name><name><surname>Salenius</surname><given-names>JP</given-names></name><name><surname>Nikkil&#x000e4;</surname><given-names>M</given-names></name><name><surname>Hannu</surname><given-names>J</given-names></name><name><surname>Koivula</surname><given-names>T</given-names></name><name><surname>Ebeling</surname><given-names>F</given-names></name><name><surname>Ehnholm</surname><given-names>C</given-names></name></person-group><article-title>Apolipoprotein E polymorphism, serum lipids, myocardial infarction and severity of angiographically verified coronary artery disease in men and women</article-title><source>Atherosclerosis</source><year>1995</year><volume>114</volume><fpage>83</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">7605379</pub-id><pub-id pub-id-type="doi">10.1016/0021-9150(94)05469-Y</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>BV</given-names></name><name><surname>Gidding</surname><given-names>SS</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name></person-group><article-title>Association of apolipoprotein E phenotype with plasma lipoproteins in African -American and white young adults</article-title><source>Am J Epidemiol</source><year>1998</year><volume>148</volume><fpage>859</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">9801016</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ikewaki</surname><given-names>K</given-names></name><name><surname>Rader</surname><given-names>DJ</given-names></name><name><surname>Zech</surname><given-names>LA</given-names></name><name><surname>Brewer</surname><given-names>JrHB</given-names></name></person-group><article-title>In vivo metabolism of apolipoproteins AI and E in patients with abetalipoproteinemia: implications for the roles of apolipoprotein B and E in HDL metabolism</article-title><source>J Lip Res</source><year>1994</year><volume>35</volume><fpage>1809</fpage><lpage>1819</lpage></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>LJ</given-names></name><name><surname>Connelly</surname><given-names>PW</given-names></name><name><surname>Nancoo</surname><given-names>D</given-names></name><name><surname>Wood</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>ZJ</given-names></name><name><surname>Mapire</surname><given-names>G</given-names></name><name><surname>Quinet</surname><given-names>E</given-names></name><name><surname>Tall</surname><given-names>AR</given-names></name><name><surname>Marcel</surname><given-names>Y</given-names></name><name><surname>Mc Pherson</surname><given-names>R</given-names></name></person-group><article-title>Cholesteryl ester transfer protein and high density lipoprotein responses to cholesterol feeding in men: relationship to apolipoprotein E genotype</article-title><source>J Lipid Res</source><year>1993</year><volume>34</volume><fpage>437</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">8468527</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>RA</given-names></name><name><surname>Michielli</surname><given-names>DW</given-names></name><name><surname>Glantz</surname><given-names>MD</given-names></name><name><surname>Sardy</surname><given-names>H</given-names></name><name><surname>Cohen</surname><given-names>A</given-names></name><name><surname>Goldberg</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>CD</given-names></name></person-group><article-title>Effects of different exercise training intensities on lipoprotein cholesterol fractions in healthy middle aged men</article-title><source>Am Heart J</source><year>1990</year><volume>119</volume><fpage>277</fpage><lpage>283</lpage><pub-id pub-id-type="pmid">2301216</pub-id><pub-id pub-id-type="doi">10.1016/S0002-8703(05)80017-1</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Oliveira</surname><given-names>ESER</given-names></name><name><surname>Foster</surname><given-names>D</given-names></name><name><surname>McGee Harper</surname><given-names>M</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Smith</surname><given-names>JD</given-names></name><name><surname>Breslow</surname><given-names>JL</given-names></name><name><surname>Brinton</surname><given-names>EA</given-names></name></person-group><article-title>Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II</article-title><source>Circulation</source><year>2000</year><volume>102</volume><fpage>2347</fpage><lpage>2352</lpage><pub-id pub-id-type="pmid">11067787</pub-id></citation></ref></ref-list></back></article> 